Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tefferi, Ayalew, Verstovsek, Srdan, Barosi, Giovanni, Passamonti, Francesco, Roboz, Gail J., Gisslinger, Heinz, Paquette, Ronald L., Cervantes, Francisco, Rivera, Candido E., Deeg, H. Joachim, Thiele, Juergen, Kvasnicka, Hans M., Vardiman, James W., Zhang, Yanming, Bekele, B. Nebiyou, Mesa, Ruben A., Gale, Robert P., Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/
https://ncbi.nlm.nih.gov/pubmed/19652059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados